Loading
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (4 ops.)
Latest filing published 23 Oct 2018 for Medite Cancer Diagnostics, Inc..
Filing timeline
BuySaleJohn H. Abeles
Insider track record
Disclosed buys
5
Disclosed sells
4
Signal history
Closed purchases
Market purchases
5
Positive at T+90
0%
Median T+90
-60.1%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +32.4%Entry US$0.05 · Close at T+365 US$0.07
- -86.5%Entry US$0.19 · Close at T+365 US$0.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
John H. Abeles: trading record in brief
John H. Abeles has filed trades across 4 companies (mainly through SEC (Form 4)), most often in I Flow Corp /DE/, Dusa Pharmaceuticals Inc and Medite Cancer Diagnostics, Inc. The record holds 19 filings, for trades running from 2 January 2006 to 11 October 2018.
The open-market side counts 5 purchases for €85k alongside 4 sales for €244k. Taken together, the sales exceed the purchases by €159k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 7 share grants. So far in 2018, the count stands at 2 purchases and no sales.
Half of the purchases are above €17k and half below.
Most recently, on 23 October 2018, the filings show an open-market purchase worth €17k in Medite Cancer Diagnostics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to John H. Abeles
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
40,000 sharesCommon StockSEC:0001415889-18-001538:0
266,667 shares@ US$0.07540.1% of flowCommon StockSEC:0001415889-18-001538:1
Canonical exit: 9 Jan 2019 (T+90)
400,000 shares@ US$0.07559.9% of flowCommon StockSEC:0001415889-18-001103:0
Canonical exit: 1 Oct 2018 (T+90)
9,119 sharesCommon StockSEC:0001179110-11-006343:0
20,000 shares@ US$1.26Common StockSEC:0001209191-09-057858:0
Canonical exit: 16 Mar 2010 (T+90)
20,000 shares@ US$1.30Common StockSEC:0001209191-09-057858:1
Canonical exit: 17 Mar 2010 (T+90)
332,500 shares@ US$12.65Common StockSEC:0001209191-09-053368:0
7,500 shares0Common StockSEC:0001209191-09-016640:0
5,000 shares0Common StockSEC:0001209191-09-001203:0
10,000 sharesCommon Stock, $.001 parSEC:0001209191-08-020038:0
5,000 shares0Common StockSEC:0001209191-08-012889:0
5,000 shares@ US$2.05Common StockSEC:0001209191-07-063694:0
Canonical exit: 11 Feb 2008 (T+90)
2,500 shares@ US$19.71Common StockSEC:0001209191-07-048184:0
5,000 shares@ US$18.14Common StockSEC:0001209191-07-047167:0
7,500 shares@ US$19.25Common StockSEC:0001209191-07-047167:1
2,500 shares@ US$20.17Common StockSEC:0001209191-07-047167:2
5,000 shares0Common StockSEC:0001209191-07-013130:0
5,000 shares0Common StockSEC:0001209191-06-000992:0
18 of 18 declarations
